Literature DB >> 19789030

Lymph node evaluation is associated with improved survival after surgery for early stage gallbladder cancer.

Eric H Jensen1, Anasooya Abraham, Stephanie Jarosek, Elizabeth B Habermann, Waddah B Al-Refaie, Selwyn A Vickers, Beth A Virnig, Todd M Tuttle.   

Abstract

BACKGROUND: Guidelines for the current National Comprehensive Cancer Network recommend radical cholecystectomy, including hepatic resection and portal lymph node (LN) dissection, for patients with early stage gallbladder (GB) cancer. We sought to determine the survival benefit conferred by adequate LN evaluation.
METHODS: We used the surveillance, epidemiology and end results (SEER) neoplasm registry to identify patients who had an operation for GB cancer between 1988 and 2004. Patients were classified by stage of disease, operative procedure performed (cholecystectomy alone or radical resection), number of LNs evaluated (0, 1, >1), and receipt of radiation (RT). We included patients with T1B, T2, and T3 neoplasms who were LN positive or negative. Patients with T4 neoplasms and those with metastatic disease were excluded. Multivariate analysis included adjustment for age, race, sex, neoplasm grade, stage, operation performed, receipt of RT, and neoplasm registry.
RESULTS: We identified 4,614 patients who underwent operative treatment for stage 1-2B GB (including T1B-T3 and LN positive or negative) cancer between 1988 and 2004. Of 4,614 patients, 9.6% (442) had radical resection, whereas 90.4% (4,172) had cholecystectomy alone. Among patients undergoing radical resection, 56% had LNs evaluated as compared with 28% of patients after cholecystectomy. For patients with T1B and T2 neoplasms who underwent radical resection, pathologic evaluation of at least 1 LN was associated with a significant improvement in median overall survival (OS) compared with those who had no LN evaluated (123 months vs 22 months; P < .0001). Radical resection with no LN evaluation provided similar OS compared with cholecystectomy alone (22 months vs 23 months; P = NS). For patients with T3 neoplasms, radical resection, including pathologic evaluation of at least 1 LN, was also associated with improved OS compared with radical resection with no LN evaluation (12 months vs 7 months; P = .0014). Again, individuals who had radical resection without LN evaluation had similar OS compared with those who had cholecystectomy alone (7 months vs 6 months; P = NS). Individuals who had radical resection with LN evaluation were more likely to receive RT than those who had radical resection without LN evaluation (33.1% vs 19.1%; P = .002). In multivariate analysis (including adjustment for RT), however, LN evaluation was still associated with a decrease in mortality compared with no LN evaluated (HR = 0.611; 95% CI = 0.484, 0.770). The pathologic evaluation of additional LN (>1) did not provide any additional benefit compared with the evaluation of a single node (HR = 0.795; 95% CI = 0.571, 1.107). Radical resection alone (without LN evaluation) did not provide any benefit over cholecystectomy alone (HR = 1.098; 95% CI = 0.971, 1.241).
CONCLUSION: LN evaluation is a critical component of radical resection for GB cancer. In the absence of LN evaluation, radical resection provides no benefit over cholecystectomy alone.

Entities:  

Mesh:

Year:  2009        PMID: 19789030     DOI: 10.1016/j.surg.2009.06.056

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  38 in total

1.  Radical resection of gallbladder cancer: could it be robotic?

Authors:  Bai-Yong Shen; Qian Zhan; Xia-Xing Deng; Han Bo; Qin Liu; Cheng-Hong Peng; Hong-Wei Li
Journal:  Surg Endosc       Date:  2012-05-31       Impact factor: 4.584

2.  Invasion of the hepatic artery is a crucial predictor of poor outcomes in gallbladder carcinoma.

Authors:  Akihiko Kobayashi; Tatsuya Oda; Kiyoshi Fukunaga; Ryoko Sasaki; Nobuhiro Ohkohchi
Journal:  World J Surg       Date:  2012-03       Impact factor: 3.352

3.  Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer.

Authors:  Samuel J Wang; Andrew Lemieux; Jayashree Kalpathy-Cramer; Celine B Ord; Gary V Walker; C David Fuller; Jong-Sung Kim; Charles R Thomas
Journal:  J Clin Oncol       Date:  2011-11-07       Impact factor: 44.544

4.  Patterns of recurrence after resection of gallbladder cancer without routine extrahepatic bile duct resection.

Authors:  Jimme K Wiggers; Bas Groot Koerkamp; Zachri Ovadia; Olivier R C Busch; Dirk J Gouma; Thomas M van Gulik
Journal:  HPB (Oxford)       Date:  2013-11-07       Impact factor: 3.647

Review 5.  Key factors influencing prognosis in relation to gallbladder cancer.

Authors:  Charles Henry Caldow Pilgrim; Ryan T Groeschl; Kiran K Turaga; T Clark Gamblin
Journal:  Dig Dis Sci       Date:  2013-05-22       Impact factor: 3.199

Review 6.  The Landmark Series: Gallbladder Cancer.

Authors:  Adriana C Gamboa; Shishir K Maithel
Journal:  Ann Surg Oncol       Date:  2020-05-30       Impact factor: 5.344

7.  Gallbladder cancer: expert consensus statement.

Authors:  Thomas A Aloia; Nicolas Járufe; Milind Javle; Shishir K Maithel; Juan C Roa; Volkan Adsay; Felipe J F Coimbra; William R Jarnagin
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

8.  Factors that Minimize Curative Resection for Gallbladder Adenocarcinoma: an Analysis of Clinical Decision-Making and Survival.

Authors:  Breanna C Perlmutter; Robert Naples; Asif Hitawala; John McMichael; Pravallika Chadalavada; Vinay Padbidri; Abdo Haddad; Robert Simon; R Matthew Walsh; Toms Augustin
Journal:  J Gastrointest Surg       Date:  2021-02-09       Impact factor: 3.452

9.  Surgery for gallbladder cancer in the US: a need for greater lymph node clearance.

Authors:  Thuy B Tran; Nicholas N Nissen
Journal:  J Gastrointest Oncol       Date:  2015-10

10.  Adjuvant Therapy for Gallbladder Cancer: an Analysis of the National Cancer Data Base.

Authors:  Richard S Hoehn; Koffi Wima; Audrey E Ertel; Alexandra Meier; Syed A Ahmad; Shimul A Shah; Daniel E Abbott
Journal:  J Gastrointest Surg       Date:  2015-08-21       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.